Armen Shanafelt

Armen Shanafelt

President at
Abshanafelt Advisory
66 year
Health Technology
Consumer Services
Finance

Profile

Armen Shanafelt brings over 29 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures.
Previous to joining Lilly Ventures in 2009, Armen held leadership and executive positions in the R&D organizations of DNAX Research Institute, Bayer Pharmaceuticals, Roche Diagnostics, and Eli Lilly and Company.
Armen currently serves as a director on the boards of Aeglea BioTherapeutics (NASDAQ: AGLE), Aileron Therapeutics (NASDAQ: ALRN), Protagonist Therapeutics (NASDAQ: PTGX), Surface Oncology (NASDAQ: SURF), Sutro Biopharma and Symic Biomedical.
He is a Kauffman Fellow (Class 14).
Armen received his B.S.
Degree in Chemistry and Physics from Pacific Lutheran University, and his Ph.D.
in Chemistry from the University of California, Berkeley.

Armen Shanafelt active positions

CompaniesPositionStart
Abshanafelt Advisory
President 2020-12-31

Former positions of Armen Shanafelt

CompaniesPositionEnd
SURFACE ONCOLOGY, INC. Director/Board Member 2023-09-07
SPYRE THERAPEUTICS, INC. Chairman 2018-12-31
Private Equity Investor 2020-11-30
REIN THERAPEUTICS INC. Director/Board Member 2019-06-18
Director/Board Member 2019-05-31
See the detail of Armen Shanafelt's experience

Training of Armen Shanafelt

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

81

1st degree connections

17

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies17

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Health Technology

DNAX Research, Inc.

Health Technology

Health Technology

Abshanafelt Advisory

  1. Stock Market
  2. Insiders
  3. Armen Shanafelt